Niessner, Martin

[["dc.bibliographiccitation.firstpage","292"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","VISZERALCHIRURGIE"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Schuetze, Gunther"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.date.accessioned","2018-11-07T10:58:26Z"],["dc.date.available","2018-11-07T10:58:26Z"],["dc.date.issued","2007"],["dc.description.abstract","40 % of patients suffering from colorectal cancer will develop liver metastases during the course of their disease. Advances in both surgical technique and perioperative management lead to a decrease in postoperative morbidity and mortality. Against the background of an increasing understanding of tumor biology as well as excellent survival data following hepatic resection, the indication for liver resection has been extended in specialized surgical centers. Similarly the intention to treat changed from a standardized resection towards an individual and interdisciplinary therapy including preoperative chemotherapy, staged liver resection and resection of extrahepatic disease. The aim of this study is to investigate the current value of hepatic resection for colorectal liver metastases in the interdisciplinary oncological concept. It specially addresses these challenging situations where palliative chemotherapy seemed to be the only reasonable way of therapy in past."],["dc.identifier.doi","10.1055/s-2007-981332"],["dc.identifier.isi","000254585100003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50476"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1435-3067"],["dc.title","Surgical therapy for colorectal liver metastases: Prospects and limits"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","09"],["dc.bibliographiccitation.journal","Zeitschrift für Gastroenterologie"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Becker, H"],["dc.contributor.author","Langer, C"],["dc.date.accessioned","2019-11-26T13:22:46Z"],["dc.date.available","2019-11-26T13:22:46Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1055/s-0028-1089657"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62675"],["dc.language.iso","de"],["dc.relation.issn","0044-2771"],["dc.relation.issn","1439-7803"],["dc.title","Kolorektale Lebermetastasen: hat der Zeitpunkt des Auftretens eine Bedeutung für das onkologische Konzept und die Prognose?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","638"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","649"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:27:25Z"],["dc.date.available","2018-11-07T10:27:25Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-131-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m(2) per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were \"truly adjuvant.\" Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as \"possibly nonadjuvant,\" but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N=5) or relapse (N=14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The \"truly adjuvant\" patients (N=39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P<.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P=.014), and CSS (not reached vs 41.4 months; hazard ratio, 0.42; P=.014) compared with \" possibly nonadjuvant\" patients (N=24). CONCLUSIONS: Repeated RIT with I-131-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for \"truly adjuvant\" patients. However, the maximum safe dose of I-131-labetuzumab is a single administration of 50 millicuries/m(2). (C) 2016 American Cancer Society."],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.identifier.doi","10.1002/cncr.30390"],["dc.identifier.isi","000396841300015"],["dc.identifier.pmid","27763687"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43229"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:20:51Z"],["dc.date.available","2018-11-07T10:20:51Z"],["dc.date.issued","2016"],["dc.format.extent","13"],["dc.identifier.isi","000371353700041"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41966"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Repeated anti-CEA radioimmunotherapy (RIT) with 131I-Labetuzumab after complete resection of colorectal liver metastases - safety, feasibility and long-term efficacy results of a prospective phase-II-study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","08"],["dc.bibliographiccitation.journal","Zeitschrift für Gastroenterologie"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Homayounfar, K"],["dc.contributor.author","Sahlmann, C"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, J"],["dc.contributor.author","Conradi, L"],["dc.contributor.author","Braulke, F"],["dc.contributor.author","Beißbarth, T"],["dc.contributor.author","Meller, B"],["dc.contributor.author","Ghadimi, M"],["dc.contributor.author","Meller, J"],["dc.contributor.author","Goldenberg, D"],["dc.contributor.author","Liersch, T"],["dc.date.accessioned","2019-11-26T13:34:37Z"],["dc.date.available","2019-11-26T13:34:37Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1055/s-0035-1559215"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62676"],["dc.language.iso","de"],["dc.relation.issn","0044-2771"],["dc.relation.issn","1439-7803"],["dc.title","Phase II Studie mit wiederholter anti-CEA-Radioimmuntherapie (RIT) mit 131I-Labetuzumab nach kompletter Resektion kolorektaler Lebermetastasen: Langzeitsicherheit und -überleben"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer Biotherapy and Radiopharmaceuticals"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Sahlmann, C-O"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Niessner, M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T11:12:19Z"],["dc.date.available","2018-11-07T11:12:19Z"],["dc.date.issued","2008"],["dc.format.extent","524"],["dc.identifier.isi","000259167300046"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53636"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc"],["dc.publisher.place","New rochelle"],["dc.relation.conference","12th Conference on Cancer Therapy with Antibodies and Immunoconjugates"],["dc.relation.eventlocation","Parsippany, NJ"],["dc.relation.issn","1084-9785"],["dc.title","Repeated versus single dose anti-CEA radioimmunotherapy (RIT) with iodine-131-labetuzumab after R0 resection for colorectal liver metastases (CRC-LM)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]